Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BioMaxima S.A. (BMX.WA)
Lublin, MZ, PL
BioMaxima S.A. produces and distributes microbiological media, reagents, and in vitro diagnostic equipment in Poland. It offers microbiology products, including ready to use media, such as plates, bottles, bags, and media in tubes; dehydrated media; agars and peptones; and supplements. The company also provides molecular biology and cell culture products which includes real time PCR, nucleic acid isolation, NA and PCR electrophoresis, protein electrophoresis, enzymes, antibiotics, agaroses and molecular biology media, media and buffers for in vitro cultures, phenotypic micromatrices, plastics and small equipment, basic substrate components, and form. In addition, it offers laboratory diagnostics solutions for various areas of clinical chemistry, haematology, coagulology, immunochemistry, POCT, rapid tests, and blood collection systems; and disposable materials comprising microbiology, dispensing equipment, tubes, plugs, tripods, capillaries, equipment, aspiration-vacuum system, containers, tank for analysers, urine analysis, microscope slides, reagent tubes, autoclave equipment, and pliers and scissors. BioMaxima S.A. was founded in 1997 and is headquartered in Lublin, Poland.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.18% | -1.28% | -8.35% | -11.80% | -13.92% | -12.87% | -25.54% | -56.79% | -60.73% | +134.42% | +36.20% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Equipment & Services: +14.1%+15.2% ★ Q1'26: -7.6% (vs Q1'25)
-
EPS growth Medical - Equipment & Services: +15.4%-80.8% Q1'26: -44.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Equipment & Services: -3.5%0.0% Q1'26: -20.0% (vs Q1'25)
-
EBIT margin Medical - Equipment & Services: +1.1%-0.2% Q1'26: +2.9% (vs Q1'25)
-
ROIC Medical - Equipment & Services: +2.4%-0.1% Q1'26: +2.1% (vs Q1'25)
-
Share dilution Medical - Equipment & Services: -2.1%+0.0% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Equipment & Services: 0.31×4.05× Q1'26: 2.96× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
46.79M
est: 46.20M (+1.3%)
|
52.85M
est: 53.30M (-0.8%)
|
60.90M
est: 59.80M (+1.8%)
|
76.80M
76.80M – 76.80M
+28.4% YoY
|
86.00M
86.00M – 86.00M
+12.0% YoY
|
90.00M
90.00M – 90.00M
+4.7% YoY
|
93.70M
93.70M – 93.70M
+4.1% YoY
|
97.70M
97.70M – 97.70M
+4.3% YoY
|
| EBITDA |
3.28M
est: 7.36M (-55.4%)
|
4.65M
est: 7.14M (-35.0%)
|
3.57M
est: 8.02M (-55.5%)
|
10.29M
10.29M – 10.29M
+28.4% YoY
|
11.53M
11.53M – 11.53M
+12.0% YoY
|
12.06M
12.06M – 12.06M
+4.7% YoY
|
12.56M
12.56M – 12.56M
+4.1% YoY
|
13.10M
13.10M – 13.10M
+4.3% YoY
|
| EBIT |
796.0K
est: 5.73M (-86.1%)
|
1.28M
est: 4.87M (-73.6%)
|
-135.0K
est: 5.46M (-102.5%)
|
7.01M
7.01M – 7.01M
+28.4% YoY
|
7.85M
7.85M – 7.85M
+12.0% YoY
|
8.22M
8.22M – 8.22M
+4.7% YoY
|
8.56M
8.56M – 8.56M
+4.1% YoY
|
8.92M
8.92M – 8.92M
+4.3% YoY
|
| Net Income |
586.0K
est: 5.87M (-90.0%)
|
535.0K
est: 3.77M (-85.8%)
|
105.0K
est: 4.19M (-97.5%)
|
7.97M
7.97M – 7.97M
+90.0% YoY
|
11.74M
11.74M – 11.74M
+47.4% YoY
|
12.58M
12.58M – 12.58M
+7.1% YoY
|
12.58M
12.58M – 12.58M
+0.0% YoY
|
13.00M
13.00M – 13.00M
+3.3% YoY
|
| SGA |
19.30M
est: 6.27M (+207.8%)
|
1.81M
est: 7.00M (-74.2%)
|
1.81M
est: 7.86M (-77.0%)
|
10.09M
10.09M – 10.09M
+28.4% YoY
|
11.30M
11.30M – 11.30M
+12.0% YoY
|
11.83M
11.83M – 11.83M
+4.7% YoY
|
12.31M
12.31M – 12.31M
+4.1% YoY
|
12.84M
12.84M – 12.84M
+4.3% YoY
|
| EPS |
0.14
est: 1.40 (-90.0%)
|
0.13
est: 0.90 (-85.6%)
|
0.03
est: 1.00 (-97.5%)
|
1.90
1.90 – 1.90
+90.0% YoY
|
2.80
2.80 – 2.80
+47.4% YoY
|
3.00
3.00 – 3.00
+7.1% YoY
|
3.00
3.00 – 3.00
+0.0% YoY
|
3.10
3.10 – 3.10
+3.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-28 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-27 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-26 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-25 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-22 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-21 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-20 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-19 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-18 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-15 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-14 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | B- | 2/5 | 1/5 | 3/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | B- | 2/5 | 1/5 | 3/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | B- | 2/5 | 1/5 | 3/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Henryk Lewczuk | Chief Financial Officer & Member of the Management Board | — | male |
| Lukasz Urban | President of the Management Board | — | male |
| Piotr Janowski | Chief Operating Officer & Member of the Management Board | — | male |
| Zaneta Homenda | Chief Accounting Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BMX.WA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
